Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Samsung Bioepis Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

25 comunicati stampa

Guarda tutti i comunicati
28/04/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Salute
Imprese
Associazioni/Professionisti
Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
27/04/2026
Industria
Biotecnologia
Farmaceutica
Salute
Sanità
Samsung Bioepis Releases Second Quarter 2026 US Biosimilar Market Report
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
20/04/2026
Eventi
Industria
Scienza
Ingegneria
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
17/04/2026
Eventi
Industria
Salute
Vetrine/Shopping
Medicina - Varie
Farmaceutica
Biotecnologia
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 2026
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
14/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
18/03/2026
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
15/03/2026
Biotecnologia
Salute
Scienza
Farmaceutica
Mercato del lavoro
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
23/01/2026
Samsung Bioepis Releases First Quarter 2026 US Biosimilar Market Report, Providing Updates to Evolving Drug Pricing Models
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
02/01/2026
Industria
Biotecnologia
Farmaceutica
Ottica
Salute
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
22/12/2025
Biotecnologia
Farmaceutica
Salute
Sanità
Industria
Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0